CN110087642B - 偏头痛的预防和治疗 - Google Patents

偏头痛的预防和治疗 Download PDF

Info

Publication number
CN110087642B
CN110087642B CN201780079158.4A CN201780079158A CN110087642B CN 110087642 B CN110087642 B CN 110087642B CN 201780079158 A CN201780079158 A CN 201780079158A CN 110087642 B CN110087642 B CN 110087642B
Authority
CN
China
Prior art keywords
migraine
βhb
compound
salts
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780079158.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN110087642A (zh
Inventor
埃琳娜·格罗斯
德克·费歇尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaets Kinderspital beider Basel UKBB
Original Assignee
Universitaets Kinderspital beider Basel UKBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaets Kinderspital beider Basel UKBB filed Critical Universitaets Kinderspital beider Basel UKBB
Publication of CN110087642A publication Critical patent/CN110087642A/zh
Application granted granted Critical
Publication of CN110087642B publication Critical patent/CN110087642B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201780079158.4A 2016-12-21 2017-12-20 偏头痛的预防和治疗 Active CN110087642B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16206018 2016-12-21
EP16206018.0 2016-12-21
EP17154258 2017-02-01
EP17154258.2 2017-02-01
PCT/EP2017/083880 WO2018115158A1 (en) 2016-12-21 2017-12-20 Migraine prevention and treatment

Publications (2)

Publication Number Publication Date
CN110087642A CN110087642A (zh) 2019-08-02
CN110087642B true CN110087642B (zh) 2022-12-27

Family

ID=61005774

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780079158.4A Active CN110087642B (zh) 2016-12-21 2017-12-20 偏头痛的预防和治疗

Country Status (17)

Country Link
US (2) US11166928B2 (https=)
EP (2) EP4245368A3 (https=)
JP (2) JP7514457B2 (https=)
KR (1) KR102610870B1 (https=)
CN (1) CN110087642B (https=)
AU (2) AU2017384625B2 (https=)
CA (1) CA3046415A1 (https=)
DK (1) DK3558280T3 (https=)
ES (1) ES2948609T3 (https=)
FI (1) FI3558280T3 (https=)
HR (1) HRP20230851T1 (https=)
HU (1) HUE062536T2 (https=)
LT (1) LT3558280T (https=)
PL (1) PL3558280T3 (https=)
RU (1) RU2753057C9 (https=)
SI (1) SI3558280T1 (https=)
WO (1) WO2018115158A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
FI3558280T3 (fi) * 2016-12-21 2023-07-13 Univ Kinderspital Beider Basel Migreenin ennaltaehkäisy ja hoito
US20180177753A1 (en) 2016-12-23 2018-06-28 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for migraine symptom management
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
AU2020246928B2 (en) * 2019-03-22 2025-05-15 Société des Produits Nestlé S.A. Methods using administration of medium chain triglycerides (MCT) prior to a meal to increase ketone production from the MCTs
AU2020274805A1 (en) 2019-05-10 2021-10-28 Ketoswiss Ag Ketone bodies enclosed in microbeads
EP3956282A1 (de) * 2019-06-12 2022-02-23 IOI Oleo GmbH Verfahren zur herstellung von acylverkappten 3-hydroxycarbonsäuren sowie deren salzen und estern
CN114008014B (zh) * 2019-06-12 2024-03-22 凯托利皮克斯治疗有限责任公司 用于生产酰基封端的3-羟基羧酸的多元醇基酯的方法
US12396974B2 (en) 2020-03-27 2025-08-26 KetoneAid Ketone ester as a therapeutic treatment of Covid-19 and related viral infections
CN117677383A (zh) 2021-07-17 2024-03-08 瑞士凯托股份公司 酮体或生酮化合物与镇痛剂或抗氧化剂的组合
WO2023166069A1 (en) 2022-03-02 2023-09-07 N.V. Nutricia Fatty acids for ketosis control
CN115590963A (zh) * 2022-07-13 2023-01-13 复旦大学（Cn） 酮体、酮体诱导剂和生酮组合物中的至少一种在治疗和/或预防血小板减少症药物中的应用
KR102775899B1 (ko) 2023-12-19 2025-02-28 한림대학교 산학협력단 삽화성 편두통 및 만성 편두통 진단을 위한 정보제공 방법, 장치 및 컴퓨터 프로그램

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174979A4 (en) * 1984-03-01 1987-11-23 Vernon Erk METHOD FOR LOWERING THE BLOOD GLUCOSE LEVEL IN VERBELTIES.
JPH0665458A (ja) 1992-08-21 1994-03-08 Nippon Oil & Fats Co Ltd 塩素含有樹脂組成物
US5420335A (en) * 1993-09-30 1995-05-30 Birkhahn; Ronald H. Parenteral nutrients based on watersoluble glycerol bisacetoacetates
CN1315473C (zh) * 1997-03-17 2007-05-16 英国技术集团国际有限公司 治疗组合物
DK1123094T3 (da) 1998-09-15 2007-08-20 Btg Int Ltd Terapeutiske præparater (II)
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US7807718B2 (en) * 2006-06-30 2010-10-05 Sami A. Hashim Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
US20120034193A1 (en) 2009-01-24 2012-02-09 Daryl Rees Treatment of neurotrophic factor mediated disorders
GB201206192D0 (en) 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
CN103877118A (zh) 2014-03-11 2014-06-25 天津金耀集团有限公司 一种由醋丙甲泼尼龙、氧化锌组成的药物组合物
US20160078782A1 (en) * 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US20180200220A1 (en) * 2015-07-10 2018-07-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using ketogenic medium chain triglycerides, ketone esters, and other ketogenic sources
FI3558280T3 (fi) * 2016-12-21 2023-07-13 Univ Kinderspital Beider Basel Migreenin ennaltaehkäisy ja hoito
US20180177753A1 (en) 2016-12-23 2018-06-28 Neuroenergy Ventures, Inc. Glyceryl 3-hydroxybutyrates for migraine symptom management
US10500182B2 (en) 2018-01-10 2019-12-10 Robert Firger Compositions of ketogenic sources, micronutrients and phytochemicals for prophylaxis and mitigation of migraine headache

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Migraine improvement during short lasting ketogenesis: a proof-of-concept study;C. Di Lorenzo;《European Journal of Neurology》;20150131;第22卷(第1期);170-177 *

Also Published As

Publication number Publication date
AU2022201565A1 (en) 2022-03-31
RU2753057C9 (ru) 2021-09-10
ES2948609T3 (es) 2023-09-14
RU2019122562A3 (https=) 2021-01-27
RU2019122562A (ru) 2021-01-27
HUE062536T2 (hu) 2023-11-28
FI3558280T3 (fi) 2023-07-13
KR20190099486A (ko) 2019-08-27
KR102610870B1 (ko) 2023-12-06
CA3046415A1 (en) 2018-06-28
EP4245368A3 (en) 2024-01-03
US11890264B2 (en) 2024-02-06
AU2022201565B2 (en) 2023-07-06
CN110087642A (zh) 2019-08-02
HRP20230851T1 (hr) 2023-11-10
EP3558280A1 (en) 2019-10-30
US20190374490A1 (en) 2019-12-12
JP2020504746A (ja) 2020-02-13
WO2018115158A1 (en) 2018-06-28
DK3558280T3 (da) 2023-08-21
JP7514457B2 (ja) 2024-07-11
RU2753057C2 (ru) 2021-08-11
EP4245368A2 (en) 2023-09-20
AU2017384625B2 (en) 2021-12-16
JP2022166218A (ja) 2022-11-01
US11166928B2 (en) 2021-11-09
LT3558280T (lt) 2023-10-10
AU2017384625A1 (en) 2019-06-13
US20210338618A1 (en) 2021-11-04
PL3558280T3 (pl) 2023-10-16
EP3558280B1 (en) 2023-06-07
SI3558280T1 (sl) 2023-10-30

Similar Documents

Publication Publication Date Title
CN110087642B (zh) 偏头痛的预防和治疗
US11773051B2 (en) S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
Pezzoli et al. Levodopa in Parkinson's disease: from the past to the future
US20150057306A1 (en) Compositions comprising scopolamine and ketamine in the treatment of depression
US20230321021A1 (en) Methods of normalizing amino acid metabolism
Lal et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome
Stacy et al. Apomorphine for the acute treatment of “off” episodes in Parkinson's disease
JP2018131470A (ja) グルコーストランスポータ１欠乏の治療のためのトリヘプタノイン
CN107835695A (zh) 用于治疗自闭症的组合物和方法
Zhou et al. Ketogenic diet for neonatal hypoxic–ischemic encephalopathy
Jost et al. Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease
Stocchi et al. Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson’s disease
US20220193167A1 (en) Combination therapy for treatment of skin diseases
Włodarek The possibility of use of the ketogenic diet and medium chain triglycerides supplementation in the support therapy of Alzheimer disease
White et al. Systematic review of the use of ketones in the management of acute and chronic neurological disorders
Mundt-Petersen et al. Infusional therapies, continuous dopaminergic stimulation, and nonmotor symptoms
PT1909782E (pt) Composições que compreendem arginina e ácido r-alfa-lipóico e sua utilização para melhoramento da função sexual
Bai et al. Cognitive function after stopping folic acid and DHA intervention: an extended follow-up results from the randomized, double blind, placebo-controlled trial in older adults with mild cognitive impairment
Lewis et al. A Non-Invasive Determination of Ketosis-Induced Elimination of Chronic Daytime Somnolence in a Patient with Late-Stage Dementia (Assessed with Type 3 Diabetes): A Potential Role of Neurogenesis
White et al. Novel Metabolic Substrates for Feeding the Injured Brain
WO2026070619A1 (ja) 肝機能の改善、維持、及び／又は悪化予防用組成物
Liebowitz L-carnitine and Heart Disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant